Essentials
Essentials

•
Genetic architecture of venous thromboembolism (VTE) remains to be fully disentangled.
• 11 newly discovered candidate polymorphisms were genotyped in 3,019 VTE cases and 2,605 controls
• None of the 11 polymorphism were significantly associated with VTE risk
• Additional major efforts are needed to identify VTE-associated genetic variants
Abstract
Background Through a meta-analysis of twelve Genome-wide Association Studies, the INVENT consortium identified two novel susceptibility loci for venous thromboembolism (VTE). This project has also generated other candidates that need to be further replicated.
Objectives To assess the association with VTE of common SNPs that demonstrated strong statistical, but not genome-wide, significance in the INVENT cohorts.
Introduction
In 2015, the International Network against VENous Thrombosis (INVENT) consortium reported the results of a meta-analysis of twelve Genome-Wide Association studies (GWAS) on venous thromboembolism (VTE) [1] . In the discovery phase of this study which was composed of 7,507 VTE cases and 52,632 controls nine loci reached the genome-wide threshold of 5x10 -8 for declaring statistical significance. Three of these loci, SLC44A2, TSPAN15 and ZFPM2, had not previously been reported to associate with VTE risk. The first two replicated in three independent French case-control studies, MARTHA12, EDITH and FARIVE [1] . The association of SLC44A2 and TSPAN15 loci with VTE was also confirmed in a recent GWAS analysis of 6,135 self-reported VTE patients belonging to the 23andMe cohorts [2] . A meta-analysis conditioning on the well-established VTE-associated single nucleotide polymorphisms (SNPs) was also performed in the INVENT discovery cohorts but failed to identify any additional genome-wide significant associations [1] . However, at a lower statistical threshold of 1x10 -5 , 285 candidate SNP were identified in this conditional, 12-cohorts meta-analysis. After excluding associations at known VTE loci, and those at the ZFPM2 locus that did not replicate previously, 125 SNPs mapping to 11 loci remained. We reasoned that there might be true positive VTE-associations among these 11 loci and decided to further genotype the lead SNPs in the three French case-control studies that served as replication for the INVENT meta-analysis.
Material and Methods
Study populations
Three French case-control studies for VTE were used in this work: EDITH, FARIVE and MARTHA12. These are exactly those that had been employed for replicating the main findings of the INVENT meta-GWAS [1] . 
EDITH -
FARIVE -
The FARIVE study is a multicenter case-control study of 607 patients with a first episode of proximal DVT and/or PE [4] . DVT was diagnosed by venography and CUS while PE was diagnosed by spiral computed tomography,high probability ventilation-perfusion lung scan and pulmonary angiography. Patients younger than 18 years, with previous VT event,
that had a diagnosis of active cancer or a history of malignancy less than 5 years previously, or have a short life expectancy because of other causes, were excluded. The control group consists of age-and sex-matched individuals free of venous and arterial thrombotic disease.
Potential control subjects with cancer, liver or kidney failure, or a history of venous and/or arterial thrombotic disease are ineligible. DNA were available for 698 cases and 672 controls. 
MARTHA12 -
Single nucleotide polymorphisms genotyping and association testing
Eleven SNPs were selected for genotyping in the EDITH, FARIVE and MARTHA12 samples.
These SNPs were identified as the lead SNP (or best proxy for it) at the 11 loci that demonstrated significant association with VTE at p < 10 -5 in the INVENT meta-GWAS after adjusting for the known-and replicated-VTE associated SNPs [1] . The lead SNPs were
rs8107460, ADRA1D rs78265041 and ICOSLG rs11701174 (Table 1) . Genotyping was performed by taqman and sequenom technologies at the Centre National de Génotypage (CNG, Evry, France).
Hardy-Weinberg equilibrium was checked by means of a Chi-square test in case and control subjects from each study separately. Association of genotyped SNPs with VTE risk was assessed in each of the three studies separately by use of a logistic regression model adjusted for age and sex. After having checked for the homogeneity of the associations across these studies using the Cochran's Q statistic, results were then meta-analyzed using a fixed-effects model based on the inverse-variance weighting method. Because the aim of the project is to validate the candidate associations generated in the INVENT cohorts, onesided association tests were conducted.
Results and Discussion
The genotype distributions of all SNPs but one, the KRI1 rs8113381, were compatible with the Hardy-Weinberg equilibirum (HWE). The distribution of the KRI1 rs8113381 that served as a proxy for the rs6511703 significantly (p <10
) deviating from HWE in all studies, both in cases and controls, this SNP was then excluded from the association analysis. The minimum per-study genotyping success rate over the 10 remaining SNPs was 0.976. Results of the association tests were detailed in Table 2 . None of the tested SNPs was statistically associated with VTE in the combined samples, with the smallest p-value being p = 0.027 for the AKR1C rs115641535. Odds ratios for all SNPs were close to unity or in the opposite direction compared to the INVENT findings.
We also investigated whether these associations could be enhanced in specific subgroups of patients, and for this end patients were stratified according to the clinical manifestations of VTE (deep vein thrombosis or pulmonary embolism) or to the presence of strong genetic risk factors (F2 rs1799963 or F5 rs6025 mutations). Also in these analyses we did not observe evidence for preferential association of the tested SNPs in specific strata.
Despite an average power of ~80% to detect in the three case-control populations studied an odds ratio equal to or greater than the INVENT findings (Table 2) , we were not able to replicate any of these associations. The lack of validation of the 11 SNPs does not preclude the existence of common variants with weaker effects or with similar effect size but in no linkage disequilibrium with SNPs assessed by imputation techniques, of common variants exercing haplotype or more complex effects, or of rare variants associated with much stronger genetics effects.
Our findings suggest that none of the 11 common SNPs we selected and that demonstrate suggestive statistical evidence at p < 10 -5 (which corresponds to allelic odds ratio greater (2) Association p-value resulting from the meta-analysis of INVENT GWAS conditioning on known VTE associated SNPs (3) p-value of the test for homogeneity of association (Cochran 's Q statistic) across the twelve discovery cohorts of the INVENT consortium. (1) CACNA2D3 rs72624844 AKR1C1 rs115641535 (1) FABP6 rs72812220 WWP2 rs80215330 (1) CPAMD8 rs10421800 PPP5C rs3795043 LILRP2 rs7249176 (1) ADRA1D rs78265041 ICOSLG rs4818892 (1) 
